Biotechnology | Disease | FDA | Therapeutics
Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
On Nov. 17, 2025, Sandoz announced that TYRUKO® (natalizumab-sztn) is available to patients in the US. Developed by…